Dr. Mitchell L Jones, MD, PhD

Claim this profile
Studies Cytomegalovirus Colitis
Studies Ulcerative Colitis
1 reported clinical trial
1 drug studied

Clinical Trials Mitchell L Jones, MD, PhD is currently running

Image of trial facility.

PALI-2108

for Ulcerative Colitis

PALI-2108 is a new oral medication designed to treat ulcerative colitis (UC) by targeting the intestines. It works as a phosphodiesterase-4 (PDE4) inhibitor prodrug, meaning it becomes active only after being processed by bacteria in the colon. This targeted approach reduces the risk of side effects that can occur with other medications that affect the entire body. Recent studies have shown that patients with active UC, especially those with moderate to severe symptoms, have higher levels of PDE4 and related biomarkers. These biomarkers are linked to the severity of their disease, suggesting that inhibiting PDE4 could help manage UC effectively. The goal of this Phase 1 study is to evaluate the safety, tolerability, and how the body processes (pharmacokinetics) and responds to (pharmacodynamics) PALI-2108 in healthy volunteers. Although there are already PDE4 inhibitors on the market, PALI-2108 is a completely new compound that has not been tested in humans before. The study will involve two parts: first, participants will receive single doses of the drug, and then, in the second part, they will take it twice a day for seven days. The twice-daily dosing schedule is designed to maximize drug exposure in the colon. The investigators will also investigate how food affects the drug's absorption. Additionally, a small group of stable UC patients will be included in the study. These patients will also take PALI-2108 for seven days, allowing us to compare the safety and drug processing between healthy individuals and those with UC. The investigators will monitor important health markers and conduct tests on colon tissue to see how well the drug works and if it causes any changes in the tissue. Including UC patients early in this research is important for understanding how the drug performs in real-world conditions. This data will help refine our approach to identify which patients might benefit most from PALI-2108 in future studies. Overall, this study aims to gather crucial information about PALI-2108's safety and effectiveness, paving the way for new treatment options for patients with ulcerative colitis.
Recruiting0 awards Phase 13 criteria

More about Mitchell L Jones, MD, PhD

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Mitchell L Jones, MD, PhD has experience with
  • PALI-2108
Breakdown of trials Mitchell L Jones, MD, PhD has run
Cytomegalovirus Colitis

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mitchell L Jones, MD, PhD specialize in?
Mitchell L Jones, MD, PhD focuses on Cytomegalovirus Colitis and Ulcerative Colitis. In particular, much of their work with Cytomegalovirus Colitis has involved treating patients, or patients who are undergoing treatment.
Is Mitchell L Jones, MD, PhD currently recruiting for clinical trials?
Yes, Mitchell L Jones, MD, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Mitchell L Jones, MD, PhD has studied deeply?
Yes, Mitchell L Jones, MD, PhD has studied treatments such as PALI-2108.
What is the best way to schedule an appointment with Mitchell L Jones, MD, PhD?
Apply for one of the trials that Mitchell L Jones, MD, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.